Merck decides to pull out of diabetes research

DARMSTADT, Germany Merck KGaA has decided to stop its research and development on diabetes products even though the company is growing in revenue and has just recently purchased the company Serono, according to published reports.

Instead, the company has decided to focus its research and development on specific therapeutic areas like oncology, neurodegenerative diseases, autoimmune and inflammatory diseases, fertility, and on certain areas within endocrinology.

What will happen to Merck’s diabetes drugs on the market and in its pipeline is still not certain. The company did state though that, “As a consequence, Merck is considering not investing further into diabetes research and development but is investigating partnerships for its existing diabetes R&D projects.”